Colgate

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Colgate 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About CL

Colgate-Palmolive Co. engages in the manufacturing and distribution of consumer products. It operates through the Oral, Personal, and Home Care, and Pet Nutrition segments. 

CEO
Noel R. Wallace
CEONoel R. Wallace
Employees
33,600
Employees33,600
Headquarters
New York, New York
HeadquartersNew York, New York
Founded
1806
Founded1806
Employees
33,600
Employees33,600

CL Key Statistics

Market cap
79.09B
Market cap79.09B
Price-Earnings ratio
36.94
Price-Earnings ratio36.94
Dividend yield
2.14%
Dividend yield2.14%
Average volume
6.23M
Average volume6.23M
High today
$98.20
High today$98.20
Low today
$96.42
Low today$96.42
Open price
$97.35
Open price$97.35
Volume
5.40M
Volume5.40M
52 Week high
$100.18
52 Week high$100.18
52 Week low
$74.55
52 Week low$74.55

Stock Snapshot

The current Colgate(CL) stock price is $98.11, with a market capitalization of 79.09B. The stock trades at a price-to-earnings (P/E) ratio of 36.94 and offers a dividend yield of 2.1%.

On 2026-02-24, Colgate(CL) stock traded between a low of $96.42 and a high of $98.20. Shares are currently priced at $98.11, which is +1.8% above the low and -0.1% below the high.

Colgate(CL) shares are trading with a volume of 5.4M, against a daily average of 6.23M.

During the past year, Colgate(CL) stock moved between $74.55 at its lowest and $100.18 at its peak.

During the past year, Colgate(CL) stock moved between $74.55 at its lowest and $100.18 at its peak.

CL News

Investor's Business Daily 4h
Colgate-Palmolive Stock Shines, Up 23% So Far This Year. Gets Rating Upgrade

News Colgate-Palmolive Stock Shines, Up 23% So Far This Year. Gets Rating Upgrade. Licensing Colgate-Palmolive (CL) stock is rising fast and it got a ratings go...

Colgate-Palmolive Stock Shines, Up 23% So Far This Year. Gets Rating Upgrade
Simply Wall St 23h
Does Colgate-Palmolive’s Premium Push and AI Marketing Pivot Change The Bull Case For CL?

In recent months, Colgate-Palmolive has been recast from a “boring toothpaste stock” to a broader consumer-products player, emphasizing AI-driven marketing, pre...

Does Colgate-Palmolive’s Premium Push and AI Marketing Pivot Change The Bull Case For CL?
TipRanks 2d
Colgate-Palmolive price target raised to $105 from $100 at BofA

BofA raised the firm’s price target on Colgate-Palmolive (CL) to $105 from $100 and keeps a Buy rating on the shares. Friday’s presentation at CAGNY focused on...

Analyst ratings

52%

of 23 ratings
Buy
52.2%
Hold
39.1%
Sell
8.7%

More CL News

TipRanks 2d
Colgate-Palmolive, Haryana Government Tie Up to Deliver Oral Health Education to 5.7 Million Students

Colgate-Palmolive (India) Limited ( (IN:COLPAL) ) has provided an update. Colgate-Palmolive (India) Limited has partnered with the Government of Haryana to exp...

TipRanks 2d
Colgate-Palmolive: Reaccelerating Growth from Pet Nutrition, Emerging Markets, and Innovation Makes CL a Preferred Buy

Morgan Stanley analyst Dara Mohsenian maintained a Buy rating on Colgate-Palmolive yesterday and set a price target of $100.00. Claim 50% Off TipRanks Premium U...

People also own

Based on the portfolios of people who own CL. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.